Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › MPLT
SUPERSTRING CAPITAL MANAGEMENT LP position in MPLT
MAPLIGHT THERAPEUTICS INC · Health Care
SUPERSTRING CAPITAL MANAGEMENT LP reported holding 125,432 shares of MPLT (MAPLIGHT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.5M, representing 2.84% of its reported portfolio and ranking #14 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP has disclosed MPLT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SUPERSTRING CAPITAL MANAGEMENT LP's MPLT position evolved
SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in MPLT in Q1 2026 at 192,139 shares (US$3.9M). The position peaked in Q2 2026 at 125,432 shares, worth US$4.5M. Across 2 filings, SUPERSTRING CAPITAL MANAGEMENT LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 125,432 shares valued at US$4.5M — a reduction of -66,707 shares quarter over quarter.. Notable position changes include a 35% trim in Q2 2026 (shares fell 72% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 192.14K | $3.91M | New |
| Q2 2026 | 125.43K | $4.50M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MPLT and 13F data
MPLT (MAPLIGHT THERAPEUTICS INC) is a Health Care company. 118 other funds we track also report a position in MPLT — the largest reported positions include Novo Holdings A/S (US$132.1M), FCPM III SERVICES B.V. (US$115.6M), Nan Fung Group Holdings Ltd (US$34.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MPLT
- Novo Holdings A/S 3.69M sh · $132.13M · Q2 2026
- FCPM III SERVICES B.V. 3.23M sh · $115.63M · Q2 2026
- Nan Fung Group Holdings Ltd 971.25K sh · $34.81M · Q2 2026
- 5AM Venture Management, LLC 950.01K sh · $34.05M · Q2 2026
- Sanofi 912.04K sh · $32.69M · Q2 2026
- Blue Owl Capital Holdings LP 729.93K sh · $26.16M · Q2 2026
- Paradigm Biocapital Advisors LP 685.85K sh · $24.58M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 611.45K sh · $21.91M · Q2 2026
- Velan Capital Investment Management LP 492.89K sh · $17.67M · Q2 2026
- DAFNA Capital Management LLC 171.01K sh · $6.13M · Q2 2026
- STEMPOINT CAPITAL LP 106.91K sh · $3.83M · Q2 2026
More on SUPERSTRING CAPITAL MANAGEMENT LP
FAQ
How long has SUPERSTRING CAPITAL MANAGEMENT LP held MPLT?
SUPERSTRING CAPITAL MANAGEMENT LP has disclosed MPLT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in MPLT?
As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 125.43K shares of MPLT (MAPLIGHT THERAPEUTICS INC), valued at $4.50M, representing 2.84% of its reported portfolio and ranking #14.
Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling MPLT?
In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP reduced its position in MPLT. The position peaked in Q2 2026 at 125.43K shares.
Which other funds hold MPLT?
Other major institutional holders of MPLT include Novo Holdings A/S, FCPM III SERVICES B.V., Nan Fung Group Holdings Ltd, among 118 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.